Claims for Patent: 10,493,094

Summary for Patent: 10,493,094

Title:	Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells
Abstract:	A hemostatic putty for treatment of a variety of wounds topographies, including but not limited to highly three dimensional wounds, for example gunshot wounds and impalements, is disclosed. The putty is comprised of a matrix polymer weakly crosslinked or not crosslinked such that a viscoelastic matrix is formed. The viscoelastic nature of the putty is tunable by the composition and enables the putty to conform to a variety of wound topographies. Likewise, a hemostatic polymer, for example chitosan or hydrophobically modified chitosan, is included in this matrix to impart hemostatic properties and tissue adhesive on the putty. The hemostatic polymers disclosed prevent microbial infection and are suitable for oxygen transfer required during normal wound metabolism.
Inventor(s):	Diehn; Kevin (Towson, MD), Dowling; Matthew (College Park, MD), Raghavan; Srinivasa R. (Silver Spring, MD), King; David R. (Boston, MA)
Assignee:	GEL-E, Inc. (College Park, MD) University of Maryland, College Park (College Park, MD) The General Hospital Corporation (Boston, MA)
Application Number:	15/443,062
Patent Claims:	1. A putty, comprising: a hemostatic biopolymer selected from hydrophobically modified alginate and hydrophobically modified gelatin, a secondary polymer, and wherein the secondary polymer is polyvinyl alcohol an ionic crosslinker, and a solvent. 2. The putty of claim 1, wherein the hydrophobically modified biopolymer comprises hydrophobic substituents covalently attached to the biopolymer. 3. The putty of claim 2, wherein the hydrophobic substituents comprise from eight to eighteen carbon atoms. 4. The putty of claim 3, wherein the hydrophobic modification is of 1 to 100 moles of hydrophobic substituent per 1 mole of biopolymer. 5. The putty of claim 1, wherein the hydrophobically modified alginate is selected from the group consisting of sodium alginate, potassium alginate, magnesium alginate, calcium alginate, aluminum alginate. 6. The putty of claim 1, wherein the polyvinyl alcohol is present in a concentration of between 5 wt % and 15 wt %. 7. The putty of claim 6, wherein the polyvinyl alcohol has a molecular weight in of between 50,000 Da and 300,000 Da. 8. The putty of claim 6, wherein the polyvinyl alcohol has a molecular weight in of between 125,000 Da and 140,000 Da. 9. The putty of claim 6, wherein the polyvinyl alcohol is hydrolyzed in a range of 70% to 100%. 10. The putty of claim 1, wherein the crosslinker is present in a concentration of between 0.1 wt % and 1.0 wt %. 11. The putty of claim 1, wherein the hemostatic biopolymer is present in a concentration of between 0.1 wt % and 3.0 wt %. 12. The putty of claim 1, wherein the composition of matter is capable of providing a compressing force of between 5 and 15 N, 15 and 30 N, or 0.1 and 5N. 13. The putty of claim 1, where in the crosslinker is a borate salt. 14. The putty of claim 13, wherein the borate salt is selected from the group consisting of sodium tetraborate decahydrate, sodium peroborate, and sodium metaborate. 15. The putty of claim 1, further comprising a water soluble reagent. 16. The putty of claim 15, wherein the water soluble reagent selected from the group consisting of human thrombin, bovine thrombin, recombinant thrombin, and human fibrinogen. 17. The putty of claim 1, further comprising a reagent selected from the group consisting of fibrinogen, factor VIIa, Factor XIII. 18. The putty of claim 1, further comprising a reagent that prevent microbial infections.

Details for Patent 10,493,094

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Omrix Biopharmaceuticals Ltd	EVITHROM	thrombin, topical (human)	Solution	125247	August 27, 2007	10,493,094	2033-03-13
Omrix Biopharmaceuticals Ltd	EVITHROM	thrombin, topical (human)	For Injection	125247	September 17, 2009	10,493,094	2033-03-13